New Formulations of Levothyroxine in the Treatment of Hypothyroidism: Trick or Treat?
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Background: Levothyroxine (LT4) as a medication is used by up to 5.3% of the adult population. For optimal efficacy, the traditional tablet formulation (LT4tab) requires that patients avoid concomitant ingestion with food, drinks, and certain medications, as well as excellent patient compliance. Some comorbidities influence bioavailability of LT4 and may mandate repeated dose adjustments. Summary: New LT4 formulations (soft gel [LT4soft] and liquid [LT4liq]) containing predissolved LT4 are claimed to improve bioavailability, presumably by facilitating absorption. Thus, these formulations may well be more suitable than LT4tab for patients whose daily requirements are subjected to variations in bioavailability. Here, we review the evidence and indications for use of new LT4 formulations and highlight areas of uncertainty that are worthy of further investigation. While bioequivalence is established for LT4soft and LT4liq administered to healthy volunteers compared with LT4tab in pharmacokinetic (PK) studies, therapeutic equivalence of the new formulations seems to be different in several clinical settings. Some evidence suggests that new formulations of LT4 may mitigate against the strict requirements relating to concomitant ingestion with food, drinks, and certain medications, which apply to traditional LT4 tablets. The principal indication is in selected patients with disease fluctuations and intermittent therapies with interfering medications, where the need for frequent dose adjustments and office visits may be diminished. Whether the use of LT4soft or LT4liq in patients with impaired gastric acid secretion results in better control of hypothyroidism than LT4tab remains unclear. Conclusions: The evidence in favor of using LT4soft and LT4liq in clinical practice over LT4tab is weak, and the underlying putative PK mechanisms unclear. Additional studies to investigate these potential benefits, define the cost-effectiveness, and understand the PK mechanisms involved with new LT4 formulations are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · cited 1×
“Current guidelines recommend that brand and formulation of LT4 should not be altered, unless there is a clinical indication (32,33).”
Global epidemiology of hyperthyroidism and hypothyroidism
Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.18 · Cited by 1,552
A review of disintegration mechanisms and measurement techniques
Markl, D., & Zeitler, J. A. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2129-z · Cited by 439 · cited 1×
“Excipients are major determinants of disintegration and dissolution (12,17,18).”
Thyroxine in Goiter, Helicobacter pylori Infection, and Chronic Gastritis
Centanni, M., Gargano, L., Canettieri, G., Viceconti, N., Franchi, A., Fave, G. D., & Annibale, B. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043903 · Cited by 329 · cited 3×
“Patients with stable comorbidities can be managed with higher than average doses of LT4tab (21,104).”
Feller, M., Snel, M., Moutzouri, E., Bauer, D. C., de Montmollin, M., Aujesky, D., Ford, I., Gussekloo, J., Kearney, P. M., Mooijaart, S., et al. (2018) · JAMA · doi:10.1001/jama.2018.13770 · Cited by 266 · cited 1×
“While biochemical euthyroidism (normal serum thyrotropin [TSH]) can be achieved in patients treated with levothyroxine (LT4), quality of life (QoL) may not be restored (8,9).”
Hadlow, N. C., Rothacker, K. M., Wardrop, R., Brown, S. J., Lim, E. M., & Walsh, J. P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4223 · Cited by 203
Altered intestinal absorption of L-thyroxine caused by coffee
Benvenga, S., Bartolone, L., Pappalardo, M. A., Russo, A., Lapa, D., Giorgianni, G., Saraceno, G., & Trimarchi, F. (2008) · Thyroid · doi:10.1089/thy.2007.0222 · Cited by 191 · cited 1×
“PPI potency, dosage, and routes of administration as well as the different LT4tabs containing different excipients may account for these Clinical studies showed reduced efficacy of LT4tab when taken with PPIs (21,74,90), calcium (63,86), iron (63), se-velamer (99), and espresso coffee (50,73,98).”
Gastrointestinal malabsorption of thyroxine
Virili, C., Antonelli, A., Santaguida, M. G., Benvenga, S., & Centanni, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00168 · Cited by 164 · cited 3×
“‘‘Refractory’’ hypothyroidism may be caused by gastrointestinal diseases and interfering medications (12,13).”
Winther, K. H., Cramon, P., Watt, T., Bjorner, J. B., Ekholm, O., Feldt-Rasmussen, U., Groenvold, M., Rasmussen, Å. K., Hegedüs, L., & Bonnema, S. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0156925 · Cited by 152 · cited 1×
“While biochemical euthyroidism (normal serum thyrotropin [TSH]) can be achieved in patients treated with levothyroxine (LT4), quality of life (QoL) may not be restored (8,9).”
Self-citationAspects of the absorption of oral L-thyroxine in normal man
Wenzel, K. W., & Kirschsieper, H. E. (1977) · Metabolism · doi:10.1016/0026-0495(77)90121-4 · Cited by 151 · cited 2×
“Decreased dissolution may result from raised gastric pH due to antacids, proton pump inhibitors (PPIs), atrophic gastritis, Helicobacter pylori infection (21), delayed gastric emptying (22), food, and drinks other than plain water (23,24).”
Cited by
Primary hypothyroidism and quality of life
Hegedüs, L., Bianco, A. C., Jonklaas, J., Pearce, S. H., Weetman, A. P., & Perros, P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00625-8 · Cited by 144
Self-citationOptimal thyroid hormone replacement
Jonklaas, J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab031 · Cited by 89
Perros, P., Van Der Feltz‐Cornelis, C., Papini, E., Nagy, E. V., Weetman, A. P., & Hegedüs, L. (2023) · Clinical Endocrinology · doi:10.1111/cen.14473 · Cited by 65
Self-citationRiis, K. R., Frølich, J. S., Hegedüs, L., Negro, R., Attanasio, R., Nagy, E. V., Papini, E., Perros, P., & Bonnema, S. J. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01555-y · Cited by 37
Self-citationBednarczuk, T., Attanasio, R., Hegedüs, L., Nagy, E. V., Negro, R., Papini, E., Perros, P., & Ruchała, M. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0048 · Cited by 33
Self-citation
Metadata
- Authors
- Nagy, E. V., Perros, P., Papini, E., Katko, M., & Hegedüs, L.
- Venue
- Thyroid
- Publisher
- SAGE Publications
- Published
- 2021-02-01
- Volume
- 31
- Issue
- 2
- Pages
- 193-201
- ISSN
- 1050-7256 (ISSN-L)
- 1557-9077
- OpenAlex
- W3089904299
- Cited by
- 63
- References
- 71
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Formulations of Levothyroxine in the Treatment of Hypothyroidism: Trick or Treat? https://app.cochat.ai/papers/10.1089/thy.2020.0515
- The paper
- Nagy, E. V., Perros, P., Papini, E., Katko, M., & Hegedüs, L. (2021). New Formulations of Levothyroxine in the Treatment of Hypothyroidism: Trick or Treat? Thyroid. https://doi.org/10.1089/thy.2020.0515
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.